cisplatin,nivolumab
pdl,bms
['lba443', 'nivolumab', 'cisplatin', 'check,mate,274', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', ' uc,(-ucsd),(-ucsf),', 'bristol', 'pdl ']
a takeover of for onclive update for adjuvant nivo in uc continues to show dfs in itts and pd-l1 +ves. 2nd endpoint of os still not available! os benefit in pd-l1 -ves (75% of pts) likely to be inferior to +ves. was the ema right to restrict use to +ves? #gu23 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.